RS for 40-year-old, 0.8-cm node-neg ER+ IDC? A pt w/ 3.0-cm tumor?

Would you order an Oncotype DX assay for a 40 yo premenopausal woman with a 0.8-cm, node-negative, ER-positive, HER2-negative IDC?

Would you order an Oncotype DX assay for a 40 yo premenopausal woman with a 3.0-cm, node-negative, ER-positive, HER2-negative IDC?

RS for 70-year-old, 1.5-cm node-neg ER+ IDC? After 5 y continue/stop adj anastrozole?

Would you order an Oncotype DX assay for a 70-year-old postmenopausal woman with a 1.5-cm, node-negative, ER-positive, HER2-negative IDC?

Would you likely recommend that a 70-year-old postmenopausal woman with a 1.5-cm, node-negative IDC who received adjuvant TC and recently completed 5 years of anastrozole without problems continue or stop anastrozole therapy?

Oncotype DX^® Recurrence Score^® (RS) for 40-year-old, 1.5-cm node-neg ER+ IDC? After 5 y continue/stop adj tamoxifen?

Would you likely order an Oncotype DX^® assay for a 40-year-old premenopausal woman with a 1.5-cm, node-negative, ER-positive, HER2-negative IDC?

RS for 40-year-old, 1.5-cm node+ (1 node) ER+ IDC? No. of MammaPrint^® (70-gene signature) assays ordered in past 1 y?

Would you order an Oncotype DX assay for a 40-year-old premenopausal woman with a 1.5-cm, ER-positive, HER2-negative IDC and 1 positive node?

Approximately how many MammaPrint^® assays have you ordered in the past year?

RS for 40-year-old, 0.8-cm node-neg ER+ IDC? A pt w/ 3.0-cm tumor?

Would you order an Oncotype DX assay for a 40 yo premenopausal woman with a 0.8-cm, node-negative, ER-positive, HER2-negative IDC?

Would you order an Oncotype DX assay for a 40 yo premenopausal woman with a 3.0-cm, node-negative, ER-positive, HER2-negative IDC?

RS for 70-year-old, 1.5-cm node-neg ER+ IDC? After 5 y continue/stop adj anastrozole?

Would you order an Oncotype DX assay for a 70-year-old postmenopausal woman with a 1.5-cm, node-negative, ER-positive, HER2-negative IDC?

Would you likely recommend that a 70-year-old postmenopausal woman with a 1.5-cm, node-negative IDC who received adjuvant TC and recently completed 5 years of anastrozole without problems continue or stop anastrozole therapy?

Oncotype DX^® Recurrence Score^® (RS) for 40-year-old, 1.5-cm node-neg ER+ IDC? After 5 y continue/stop adj tamoxifen?

Would you likely order an Oncotype DX^® assay for a 40-year-old premenopausal woman with a 1.5-cm, node-negative, ER-positive, HER2-negative IDC?

TARGET AUDIENCE
This activity is intended for medical oncologists, hematologist-oncologists, hematology-oncology fellows, oncology nurses, radiation oncologists, breast/general surgeons and other healthcare practitioners involved in the management of breast cancer.

OVERVIEW OF ACTIVITY
Breast cancer remains the most frequently diagnosed type of cancer in women, with an estimated 234,580 new cases and 40,030 deaths in the United States in 2013. Advances in screening and prevention have resulted in a steady down-stage migration at the time of disease presentation, and the number of individuals living with breast cancer has increased substantially, as has the population “at risk” for recurrent disease.

Extra Commentary

Prior to ASCO 2013, were you using calcium and magnesium to prevent or mitigate oxaliplatin-induced sensory neuropathy (Loprinzi CL et al. Proc ASCO 2013;Abstract 3501)?

Extra Commentary

Will the results of the Phase III FIRE-3 study comparing first-line FOLFIRI/bevacizumab to FOLFIRI/cetuximab in patients with KRAS WT mCRC change your practice (Heinemann V et al. Proc ASCO 2013;Abstract LBA3506)?

OVERVIEW OF ACTIVITY

Each year, thousands of clinicians, basic scientists and other industry professionals sojourn to major international oncology conferences to hone their skills, network with colleagues and learn about recent advances altering state-of-the-art management in hematologic oncology. As such, these events have become global stages where exciting science, cutting-edge concepts and practice-changing data emerge on a truly grand scale. This massive outpouring of information has enormous benefits for the hematologic oncology community, but the truth is it also creates a major challenge for practicing oncologists and hematologists.

OVERVIEW OF ACTIVITY
Each year, thousands of clinicians, basic scientists and other industry professionals sojourn to major international oncology conferences, like the American Society of Clinical Oncology (ASCO) and European Hematology Association (EHA) annual meetings, to hone their skills, network with colleagues and learn about recent advances altering state-of-the-art management in hematologic oncology. As such, these events have become global stages where exciting science, cutting-edge concepts and practice-changing data emerge on a truly grand scale. This massive outpouring of information has enormous benefits for the hematologic oncology community, but the truth is it also creates a major challenge for practicing oncologists and hematologists.